



Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Date: 11/05/2022

Ref: 21-22 631

Dear Sir or Madam,

Freedom of Information request

Firstly, please accept our sincere apologies in the delay in providing you with a response.

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 10/03/2022. Please see responses to your requests below.

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents?

Agents	Patients
Carboplatin (monotherapy or in combination with 5-FU)	<4
Cisplatin (monotherapy or in combination with 5-FU)	13
Cetuximab with/without chemotherapy	0
Cetuximab with radiotherapy	0
Pembrolizumab monotherapy	7
Pembrolizumab with chemotherapy	0
Nivolumab	<4
Docetaxel (monotherapy or in combination with 5-FU)	<4
Fluorouracil (5FU)	0
Radiotherapy only	0
Other	<4

We are unable to provide precise figures when patient numbers are less than 4 due to the risk that individuals could be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

• Total number of head and neck cancer patients?

There were 25 patients.

• Number of locally advanced head and neck cancer patient?

The Trust does not record this level of information. Therefore, to extract this information, we would have to search through a significant number of patient records. It is estimated that to attempt to retrieve all the information you require would take a considerable amount of retrieval time, which would exceed 18 hours. This would exceed the appropriate limit for dealing with a Freedom of Information Request, in terms of costs and therefore Section 12(1) of the Freedom of Information Act 2000 applies.

• Number of recurrent and/or metastatic head and neck cancer patients?

Zero.

3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents?

Agents	Patients
Atezolizumab	<4
Carboplatin with Gemcitabine	12
Carboplatin single or in any other combination	<4
Cisplatin with Gemcitabine	12
Cisplatin single or in any other combination	<4
Nivolumab	0
Pembrolizumab	<4
Any other regimen including Paclitaxel	<4
Any other chemotherapy regimen	<4
Other active systemic anti-cancer therapy - Avelumab	<4
Palliative care only	0

Please see

exemption in question 1

4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

The study ATLANTIS which is an adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer had 5 recruits between 2017-19. The study is not recruiting at present.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team